Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon

Calliditas Therapeutics to present and attend investor conferences in November 2018

Interim Report Q3, 2018

Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update

Calliditas Therapeutics’ nomination committee for the AGM 2019

Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study

Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN)

Interim Report Q2, 2018

Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update

The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts

Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry

Number of shares and votes in Calliditas Therapeutics

Exercise of over-allotment option and end of the stabilization period

Stabilization notice

Number of shares and votes in Calliditas Therapeutics

Trading in Calliditas’ share commences today on Nasdaq Stockholm

Calliditas announces listing on Nasdaq Stockholm and related prospectus